In parallel, circulating ADM levels have been identified as a potential biomarker for COPD exacerbation [96], while proadrenomedullin (proADM) has been proposed as a predictor of survival in COPD patients [97]. The gene discussed is ADM; the disease is chronic obstructive pulmonary disease.